Lonza

Lonza, headquartered in Switzerland, operates in the Pharmaceutical Preparation Manufacturing industry. In 2025, Lonza's total reported carbon emissions were approximately 2.71 billion kg CO2e. This included around 317 million kg CO2e from Scope 1 emissions, 93 million kg CO2e from market-based Scope 2 emissions, and approximately 2.30 billion kg CO2e from Scope 3 emissions. Key contributors to Scope 3 emissions included purchased goods and services (approximately 1.53 billion kg CO2e), capital goods (around 304 million kg CO2e), and upstream transportation and distribution (about 103 million kg CO2e).

Looking back, Lonza's total emissions were approximately 2.36 billion kg CO2e in 2024, comprising around 343 million kg CO2e (Scope 1), 141 million kg CO2e (market-based Scope 2), and about 1.88 billion kg CO2e (Scope 3). In 2023, total emissions were approximately 2.46 billion kg CO2e, with Scope 1 at about 321 million kg CO2e, market-based Scope 2 at around 202 million kg CO2e, and Scope 3 at approximately 1.94 billion kg CO2e.

Lonza has set ambitious climate commitments, with Science Based Targets initiative (SBTi) approved targets. The company commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, using a 2021 base year. Additionally, Lonza aims for 79% of its suppliers, by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by 2028. The company also states an ambition to achieve net-zero emissions by 2050 or earlier. Lonza has also set intensity targets, aiming to reduce its Scope 1 and 2 GHG emissions intensity by 50% by 2030 compared to 2018 levels.